Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 07-Sep-2018

Souvie Biodelivery, LLC

Abstract

One of the biggest challenges in most therapies is getting molecules to the right place in the right cell at the right time. Despite the marked improved outcomes of arresting some types of cancer with drugs, this approach has its limitations. One limitation in treating this disease is that the drugs have toxic effects on both cancer and healthy cells. These broad spectrum effects account for their side effects such as nausea/vomiting, hair loss and opportunistic infections, which may even have fatal consequences. To circumvent this drawback, we developed a novel drug delivery platform using nanotechnology and cell surface display technology. We anticipate that these "smart" drug delivery vehicles containing therapeutic cargo can sense where they are in the body and move the cargo to where it needs to go such as tumors. As a result, their desired efficacy is expected to be enhanced at the same time the side effects can be ameliorated or even eliminated. Such outcome will make our product very attractive for further refinement. In 2016, the drug delivery system market size was valued at $510B with an annual growth rate of 6.9% and it is expected to reach approximately $900B by 2025. Our customers and potential partners are pharmaceutical companies. Unlike the present drug delivery platforms on the market, our technology also has the advantage of being degradable, harmless to humans, cheap to produce and non-immunogenic.

Additional Questions

Who is your customer?

Pharmaceutical companies, contract research organizations and research laboratories. Our end users are cancer patients.

What problem does this idea/product solve or what market need does it serve?

The present available drug delivery platforms lack sufficient selectivity to discriminate between cancerous and healthy cells. As a consequence, their payload is delivered also to healthy cells which destroys them. Accordingly, patients undergoing chemotherapy can experience side effects such as nausea/vomiting, hair loss which also render them susceptible to opportunistic infections that may even be fatal.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Our engineered novel drug delivery platform is expected to be superior because of improvements in its payload delivery to just designated cancerous targets. This advantage is realized due to the fact that the system has built-in biological components that serve as a homing device for solely presenting the drugs to cancer cells and trigger release of the vehicle's contents. This unique intrinsic targeting design is anticipated to minimize or completely eliminate side effects of chemotherapy.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

The President and founder, Souvenir Tachado MD, is a highly experienced immunologist and biologist who has also broad scientific and leadership experience conducting research in virology, molecular biology, and cell biology over the course of 30 years. His research accomplishments and experience in the field of cell biology, together with his managerial, technical expertise and leadership skills equip him with the knowledge required to effectively execute and develop the proposed novel drug delivery vehicle system. It is anticipated that this platform will deliver the payload to specific designated target areas, which can improve cancer patient treatment outcome. Seyha Seng, PhD possesses the necessary experience to undertake this task based on an outstanding record of achievement in both biopharmaceutics and with one start-up. Peter Reinach, PhD is a Distinguished Teaching Professor Emeritus who is now employed by Wenzhou Medical University in China. His ophthalmic research career dealing with ocular diseases for about 45 years was funded by numerous NIH grants and the pharmaceutical industry as well as serving as their consultant in the US and Japan. He has coauthored more than 175 publications in high impact peer-reviewed journals. This consultant continues to provide us with valuable advice and essential guidance in project development since its inception. Finally, our team has a clear understanding of our mission and is highly committed to realize its goal. ‬‬‬‬